Repligen Corporation Reports 14.8% Revenue Growth to $194.3 Million in Q1 2026

Repligen Corporation reported its financial results for the first quarter of 2026, revealing a total revenue of $194.3 million, a 14.8% increase from $169.2 million in the same period last year. The growth was primarily driven by a $25.1 million rise in product revenue, which reached $194.2 million, with notable contributions from all product franchises. The company also recognized a loss of $13.8 million from the sale of Polymem S.A.S., which impacted its overall profitability. Despite this, Repligen achieved a net income of $8.3 million, or $0.15 per diluted share, compared to $5.8 million, or $0.10 per diluted share, in the prior year.

In terms of operational metrics, Repligen's gross margin improved to 55.7% from 54.0% year-over-year, attributed to higher product sales and a favorable product mix. The company’s total costs and operating expenses increased by 9.7% to $178.3 million, driven by higher costs of goods sold and increased research and development expenses, which rose by 19.3% to $14.5 million. Selling, general, and administrative expenses also saw an uptick of 8.2%, reflecting investments in personnel to support growth.

Repligen's strategic developments included the completion of the acquisition of 908 Devices' bioprocessing analytics portfolio in March 2025, which contributed $2.4 million in revenue during the quarter. The company also initiated restructuring activities aimed at optimizing its global manufacturing footprint, which are expected to enhance operational efficiency. As of March 31, 2026, Repligen's cash and cash equivalents stood at $582.7 million, with total liquidity of $784.5 million, reflecting a solid financial position to support ongoing operations and strategic initiatives.

Geographically, Repligen experienced revenue growth across all regions, with North America increasing by 4.8%, Europe by 22.9%, and Asia Pacific by 29.4%. The company’s customer base remains diverse, with no single customer accounting for 10% or more of total revenue. Looking ahead, Repligen anticipates continued growth driven by its expanding product portfolio and market demand for bioprocessing technologies, while also navigating challenges such as inflation and supply chain pressures. The company remains committed to investing in research and development to enhance its offerings and maintain its competitive edge in the bioprocessing sector.